Clinical characteristics of idiopathic pulmonary fibrosis patients with gender, age, and physiology staging at Okinawa Chubu Hospital

Journal of Thoracic Disease

Volumn 7, Issue 5, 2015, Pages 843-849

  Kishaba, Tomoo ^a   Shimaoka, Yousuke ^b   Fukuyama, Hajime ^c   Nagano, Hiroaki ^a   Nei, Yuichiro ^a   Yamashiro, Shin ^a   Tamaki, Hitoshi ^d  

^a Okinawa Prefectural Chubu Hospital   (Japan)

^b Department of Radiology   (Japan)

^c Yaeyama Prefectural Hospital   (Japan)

^d Sunagawa Naika Clinic   (Japan)

Author keywords

Idiopathic pulmonary fibrosis (IPF); Modified medical research council (MMRC); Mortality; Pulmonary hypertension; Staging

Indexed keywords

CARBON MONOXIDE;

ADULT; AGE; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENDER; GENDER AGE AND PHYSIOLOGY STAGING; HUMAN; JAPAN; LUNG CAPACITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTOR VARIABLE; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; VERY ELDERLY;

EID: 84930909717     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2015.04.54     Document Type: Article

References (39)

1. Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005;172:488-93.
2. Nishimura K, Kitaichi M, Izumi T, et al. Usual interstitial pneumonia: histologic correlation with high-resolution CT. Radiology 1992;182:337-42.
3. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-64.
4. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-203.
5. Fernández Pérez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010;137:129-37.
6. Okamoto T, Ichiyasu H, Ichikado K, et al. Clinical analysis of the acute exacerbation in patients with idiopathic pulmonary fibrosis. Nihon Kokyuki Gakkai Zasshi 2006;44:359-67.
7. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:963-7.
8. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-40.
9. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248-54.
10. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-4.
11. Global strategy for the diagnosis, management and prevention of COPD. Available online: www.goldcopd.org, accessed on 2 February 2013.
12. King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164:1171-81.
13. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:459-66.
14. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012;156:684-91.
15. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997;169:977-83.
16. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
17. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-6.
18. Watadani T, Sakai F, Johkoh T, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology 2013;266:936-44.
19. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003;167:962-9.
20. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43.
21. Kondoh Y, Taniguchi H, Ogura T, et al. Disease progression in idiopathic pulmonary fibrosis without pulmonary function impairment. Respirology 2013;18:820-6.
22. Hanamoto S, Ohsuji T, Tsuyuguchi I, et al. Prediction formulas for pulmonary function tests expressed in linear and exponential form for healthy Japanese adults. Nihon Kyobu Shikkan Gakkai Zasshi 1992;30:2051-60.
23. Murata K, Khan A, Herman PG. Pulmonary parenchymal disease: evaluation with high-resolution CT. Radiology 1989;170:629-35.
24. Akira M, Sakatani M, Ueda E. Idiopathic pulmonary fibrosis: progression of honeycombing at thin-section CT. Radiology 1993;189:687-91.
25. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008;246:697-722.
26. Inase N, Sawada M, Ohtani Y, et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med 2003;42:565-70.
27. Kondoh Y, Taniguchi H, Yokoi T, et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur Respir J 2005;25:528-33.
28. Watanabe N, Taniguchi H, Kondoh Y, et al. Clinical efficacy of sildenafil in interstitial pneumonia with pulmonary hypertension. Nihon Kokyuki Gakkai Zasshi 2011;49:151-5.
29. Gläser S, Obst A, Koch B, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiency. PLoS One 2013;8:e65643.
30. Kishaba T, Tamaki H, Shimaoka Y, et al. Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis. Lung 2014;192:141-9.
31. Ryerson CJ, Abbritti M, Ley B, et al. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011;16:969-75.
32. Lechtzin N, Hilliard ME, Horton MR. Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis. Chest 2013;143:1745-9.
33. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-48.
34. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7.
35. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9.
36. Taniguchi H, Kondoh Y, Ebina M, et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 2011;12:93.
37. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.
38. Okuda R, Hagiwara E, Baba T, et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 2013;107:1431-7.
39. Sakamoto S, Itoh T, Muramatsu Y, et al. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis. Intern Med 2013;52:2495-501.